menu
    • menu
    [{"orgOrder":0,"company":"Extend Biosciences","sponsor":"Integrated Medical Development | National Institute of Diabetes and Digestive and Kidney Diseases | Pharmaceutical Research Associates","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"EXT608","moa":"||PTH receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Extend Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Extend Biosciences \/ Integrated Medical Development | National Institute of Diabetes and Digestive and Kidney Diseases | Pharmaceutical Research Associates","highestDevelopmentStatusID":"6","companyTruncated":"Extend Biosciences \/ Integrated Medical Development | National Institute of Diabetes and Digestive and Kidney Diseases | Pharmaceutical Research Associates"},{"orgOrder":0,"company":"Extend Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Teriparatide","moa":"||Parathyroid hormone receptor||PTH receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Extend Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Extend Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Extend Biosciences \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Extend Biosciences

    Menu

    Extend Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Extend Biosciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Extend Biosciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teriparatide,Inapplicable

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Extend Biosciences Announces Positive Data from Phase 1 Trial of EXT608 for the Treatment of Hypoparathyroidis...

                            Details : EXT608 is a long-acting derivative of parathyroid hormone (PTH). Developed using ExtendBio’s D-VITylation® platform, the compound is fully active at the PTH receptor upon injection for the treatment of hypoparathyroidism.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            November 05, 2023

                            Lead Product(s) : Teriparatide,Inapplicable

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Extend Biosciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Extend Biosciences

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EXT608,Inapplicable

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Integrated Medical Development | National Institute of Diabetes and Digestive and Kidney Diseases | Pharmaceutical Research Associates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1 Study of EXT608 in Healthy Adults

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            June 07, 2022

                            Lead Product(s) : EXT608,Inapplicable

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Integrated Medical Development | National Institute of Diabetes and Digestive and Kidney Diseases | Pharmaceutical Research Associates

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth